ArticleMolecular oncology2015

PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.

Carmela Passaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.